Categories Earnings, Other Industries, Retail
Weakness in beer sales creeps into Anheuser Busch InBev Q3 earnings, stock tanks
Hurt by weakness in beer sales in China and the US, brewing giant Anheuser Busch InBev (NYSE:BUD) aka AB InBev reported third-quarter revenues and earnings that missed Wall Street expectations. BUD shares tanked 8.5% during pre-market hours on Friday.
BUD shares have increased 38% in the year-to-date period.
The Belgian firm reported a modest 2.7% growth in revenues to $13.17 billion, which fell short of the street consensus of $13.82 billion. Adjusted net income of $1.22 per share was, meanwhile, 9 cents short of the analysts’ target.
There has been a change in consumer preferences towards healthier drinks, primarily in the US, hurting sales of soda and beer. The world’s largest brewer was forced to buy up numerous craft brewers over the past few years to maintain its market position in the beer industry.
READ: Coca-Cola beats Q3 revenue expectations; EPS comes in line
The downbeat results and possibility of prolonged weakness has forced the company to step down its expectation for the full year. The parent of Budweiser and Corona beer now sees “moderate” EBITDA growth in FY19, compared to earlier projection of “strong” growth.
“Price increases implemented in South Korea and Brazil drove volume declines, which were exacerbated by softer consumer demand in light of difficult macroeconomic conditions,” the company said in a statement.
Earlier this month, rival firm Constellation Brands (NYSE: STZ) reported mixed quarterly results. The stock, however, fell as the company incurred a bigger loss from investments in cannabis firm Canopy Growth Corporation (GCG).
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on